Isocitrate Dehydrogenase

"Isocitrate Dehydrogenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An enzyme of the oxidoreductase class that catalyzes the conversion of isocitrate and NAD+ to yield 2-ketoglutarate, carbon dioxide, and NADH. It occurs in cell mitochondria. The enzyme requires Mg2+, Mn2+; it is activated by ADP, citrate, and Ca2+, and inhibited by NADH, NADPH, and ATP. The reaction is the key rate-limiting step of the citric acid (tricarboxylic) cycle. (From Dorland, 27th ed) (The NADP+ enzyme is EC 1.1.1.42.) EC 1.1.1.41.

Descriptor ID	D007521
MeSH Number(s)	D08.811.682.047.820.475
Concept/Terms	Isocitrate Dehydrogenase Isocitrate Dehydrogenase Dehydrogenase, Isocitrate NAD Isocitrate Dehydrogenase Dehydrogenase, NAD Isocitrate Isocitrate Dehydrogenase, NAD Isocitrate Dehydrogenase (NAD+) Isocitrate Dehydrogenase-I Isocitrate Dehydrogenase-I Isocitrate Dehydrogenase I

Below are MeSH descriptors whose meaning is more general than "Isocitrate Dehydrogenase".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Oxidoreductases [D08.811.682]
Alcohol Oxidoreductases [D08.811.682.047]
NAD (+) and NADP (+) Dependent Alcohol Oxidoreductases [D08.811.682.047.820]
Isocitrate Dehydrogenase [D08.811.682.047.820.475]

Below are MeSH descriptors whose meaning is related to "Isocitrate Dehydrogenase".

Below are MeSH descriptors whose meaning is more specific than "Isocitrate Dehydrogenase".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Isocitrate Dehydrogenase" by people in this website by year, and whether "Isocitrate Dehydrogenase" was a major or minor topic of these publications.

Bar chart showing 17 publications over 7 distinct years, with a maximum of 4 publications in 2015 and 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2012	0	1	1
2015	1	3	4
2016	1	1	2
2018	1	1	2
2020	0	1	1
2022	1	3	4
2024	3	0	3

Below are the most recent publications written about "Isocitrate Dehydrogenase" by people in Profiles.

Wu MJ, Kondo H, Kammula AV, Shi L, Xiao Y, Dhiab S, Xu Q, Slater CJ, Avila OI, Merritt J, Kato H, Kattel P, Sussman J, Gritti I, Eccleston J, Sun Y, Cho HM, Olander K, Katsuda T, Shi DD, Savani MR, Smith BC, Cleary JM, Mostoslavsky R, Vijay V, Kitagawa Y, Wakimoto H, Jenkins RW, Yates KB, Paik J, Tassinari A, Saatcioglu DH, Tron AE, Haas W, Cahill D, McBrayer SK, Manguso RT, Bardeesy N. Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity. Science. 2024 Jul 12; 385(6705):eadl6173.

View in: PubMed
Pitarresi JR, Fitzgerald KA. Unmasking immune suppression. Science. 2024 Jul 12; 385(6705):140-142.

View in: PubMed
Tropeano MP, Raspagliesi L, Bono BC, Baram A, Rossini Z, Franzini A, Navarria P, Clerici E, Bellu L, Simonelli M, Scorsetti M, Riva M, Politi LS, Pessina F. Supramaximal resection: retrospective study on IDH-wildtype Glioblastomas based on the new RANO-Resect classification. Acta Neurochir (Wien). 2024 Apr 27; 166(1):196.

View in: PubMed
Notarangelo G, Spinelli JB, Perez EM, Baker GJ, Kurmi K, Elia I, Stopka SA, Baquer G, Lin JR, Golby AJ, Joshi S, Baron HF, Drijvers JM, Georgiev P, Ringel AE, Zaganjor E, McBrayer SK, Sorger PK, Sharpe AH, Wucherpfennig KW, Santagata S, Agar NYR, Suv? ML, Haigis MC. Oncometabolite d-2HG alters T cell metabolism to impair CD8+ T cell function. Science. 2022 09 30; 377(6614):1519-1529.

View in: PubMed
Wu MJ, Shi L, Merritt J, Zhu AX, Bardeesy N. Biology of IDH mutant cholangiocarcinoma. Hepatology. 2022 05; 75(5):1322-1337.

View in: PubMed
Wu MJ, Shi L, Dubrot J, Merritt J, Vijay V, Wei TY, Kessler E, Olander KE, Adil R, Pankaj A, Tummala KS, Weeresekara V, Zhen Y, Wu Q, Luo M, Shen W, Garc?a-Beccaria M, Fern?ndez-Vaquero M, Hudson C, Ronseaux S, Sun Y, Saad-Berreta R, Jenkins RW, Wang T, Heikenw?lder M, Ferrone CR, Goyal L, Nicolay B, Deshpande V, Kohli RM, Zheng H, Manguso RT, Bardeesy N. Mutant IDH Inhibits IFN?-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma. Cancer Discov. 2022 03 01; 12(3):812-835.

View in: PubMed
Vachha BA, Huang RY. BOLD asynchrony: An imaging biomarker of tumor burden in IDH-mutated gliomas. Neuro Oncol. 2022 01 05; 24(1):88-89.

View in: PubMed
Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu JJ, Iwamoto F, Placantonakis D, Kim L, Elder B, Kaptain G, Cachia D, Moshel Y, Brem S, Piccioni D, Landolfi J, Chen CC, Gruber H, Rao AR, Hogan D, Accomando W, Ostertag D, Montellano TT, Kheoh T, Kabbinavar F, Vogelbaum MA. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. JAMA Oncol. 2020 12 01; 6(12):1939-1946.

View in: PubMed
McBrayer SK, Mayers JR, DiNatale GJ, Shi DD, Khanal J, Chakraborty AA, Sarosiek KA, Briggs KJ, Robbins AK, Sewastianik T, Shareef SJ, Olenchock BA, Parker SJ, Tateishi K, Spinelli JB, Islam M, Haigis MC, Looper RE, Ligon KL, Bernstein BE, Carrasco RD, Cahill DP, Asara JM, Metallo CM, Yennawar NH, Vander Heiden MG, Kaelin WG. Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell. 2018 09 20; 175(1):101-116.e25.

View in: PubMed
Patel SA. Enasidenib-Induced Differentiation Syndrome in IDH2-Mutant Acute Myeloid Leukemia. JAMA Oncol. 2018 08 01; 4(8):1110-1111.

View in: PubMed

People

Explore

Similar Concepts

Top Journals